Pharmaceutical Industry in Mexico to Reach $11.26B by 2022

Mexico is the second-largest pharmaceutical market in Latin America after Brazil and, in the original report’s figures, accounted for about 37% of the region’s drug sales. It was worth about US$9.35 billion in 2018, we wrote, with patented medicines making up 51% of sales, and was forecast to reach US$11.26 billion by 2022.

This brief is written for a company thinking of selling medicines into Mexico: a foreign manufacturer, a distributor, a generics maker or a supplier of services to them. It keeps the original report’s sizing as the starting point and adds what has changed since, which is mostly about who buys and how products get approved.

How big the market is depends on who you ask

The first thing an entrant learns is that published market sizes for Mexico don’t agree. The figures below all describe “the pharmaceutical market in Mexico” in some sense.

EstimateYearValueWhat it counts
Reogma original report2018US$9.35 billionMarket value, three segments
Reogma forecast2022US$11.26 billionSame basis
INEGI-based industry sales, via Expansión2022MXN 536.5 billionSales of pharmaceutical products
IMARC Group2024US$19.8 billionMarket research estimate
Statista2024US$7.39 billionNarrower consumer-market definition

Sources: Reogma 2021 report, Expansión (June 2025), IMARC Group and Statista.

At 2022 exchange rates, the MXN 536.5 billion figure is roughly US$27 billion (our conversion), more than double our forecast. It’s not the same measure. It counts industry sales, including to hospitals and the state, while our original figure appears to have been closer to a retail market view. The Statista number is lower still. Our reading is that the 2022 forecast was in the right direction but on a narrow definition, and an entrant should build its own sizing around the channel it plans to sell through.

Who buys the medicines

Mexico has two very different markets under one name. They work differently.

First, the public market. It serves patients of the social security institutes, mainly IMSS (for private-sector workers) and ISSSTE (for state employees), and the IMSS-Bienestar system for people without social insurance. The government buys for all of them, and since 2019 it has done so through large consolidated tenders rather than hospital-by-hospital purchasing. The change was meant to cut prices and corruption. It also produced well-publicized shortages while the new system bedded in, and it made public tenders a high-stakes, all-or-nothing business for suppliers.

Then the private market, which runs through pharmacy chains, independent pharmacies and private hospitals, where patients pay out of pocket. It’s where branded and over-the-counter products earn most of their margin. The original report noted that the share of the population receiving prescribed medication rose from 65% in 2012 to 77% in 2016, and that health spending was about 6% of GDP in 2017.

The two compare like this for a supplier.

FeaturePublic marketPrivate market
BuyerFederal government, consolidated tendersPharmacy chains, hospitals, patients
Price pressureVery highModerate
PaymentSlow, sometimes delayedCommercial terms
Local manufacturingFavored in tenders from 2026No formal preference

Source: Reogma summary of the policies described in this brief.

For an entrant the choice of channel decides almost everything else. Pricing, packaging, registration strategy and the size of the sales team follow from it.

Getting a product approved

Every medicine sold in Mexico needs a sanitary registration from COFEPRIS, the Federal Commission for the Protection against Sanitary Risks. In the original report’s time the agency had a large backlog and had suspended the registrations of more than 6,000 drugs, which made approvals slow and unpredictable.

That has improved. The most useful change is the abbreviated pathway. Under it, COFEPRIS relies on approvals already granted by reference regulators, including the US FDA, the European Medicines Agency, Health Canada and Swissmedic, instead of repeating the full review. According to the regulatory consultancy Freyr, the pathway targets about 45 business days for medicines, against 90 to 120 days under the standard route, subject to conditions:

  • The product must match the reference registration in brand, molecule, dose and formulation.
  • Approvals granted abroad through fast-track or simplified routes don’t qualify.
  • Full documentation in COFEPRIS formats is still required.
  • The company needs a local pharmacovigilance unit to monitor side effects.

In March 2025 COFEPRIS added a similar reliance route for Phase III clinical trials already authorized by the FDA or EMA, with a 45-calendar-day target. Mexico is cheaper than the United States for trials, and this makes it more attractive as an extra trial site.

Where the products come from

The original report found Mexico importing about US$5.4 billion of pharmaceuticals a year, about 24% of them from the United States, with Germany, France, Puerto Rico and Switzerland next. Local manufacturing exists, and production costs are about 17% below US levels, but the industry depends on imported ingredients. According to CANIFARMA, the national pharmaceutical industry chamber, Mexico imports nearly 80% of its active pharmaceutical ingredients (APIs), mostly from India and China.

The government wants to change that. Under Plan México, public tenders from 2026 give priority to laboratories that manufacture medicines and medical devices in Mexico, and procurement for 2027 and 2028 is set to favor generics made in the country, companies building new plants or warehouses, and those investing in research on new or biosimilar drugs. The state company Birmex and firms linked to it are also meant to get priority in tenders.

For an importer this is the main policy risk of the next few years. A company that only imports finished products may find public tenders harder to win, while a local manufacturing or packaging partner becomes an advantage.

What still goes wrong

Some of the original report’s risks remain the ones entrants mention first.

Counterfeit and illegal medicines were estimated at about US$1.5 billion in sales, with counterfeits making up about 80% of the illegal market. For a high-value product, brand protection, serialized packaging and controlled distribution aren’t optional. Antibiotic resistance is a second, quieter issue: a study across 47 Mexican centers found resistance as high as 19.1% in some groups of bacteria, which shapes how hospitals buy antibiotics.

Payment delays in the public system are the third. They hurt small suppliers most. Counterfeit risk is similar for nicotine and vaping products, see our report on the global tobacco industry.

A checklist for a smaller entrant

For a small or mid-sized company, the practical order of work looks like this:

  1. Decide on the channel first: public tenders, private pharmacy or both.
  2. Check whether the product already has FDA, EMA, Health Canada or Swissmedic approval, and whether it qualifies for the abbreviated pathway.
  3. Appoint a local legal representative and set up pharmacovigilance before filing.
  4. For public tenders, look for a Mexican manufacturing, packaging or distribution partner, given the Plan México preferences.
  5. Budget for slow public payment, and price for it.

For wider context, see our report on the global pharmaceutical industry, and the nutraceutical market in India shows how India, the main source of Mexico’s APIs, is building out its own health-products industry.